- Report
- April 2024
- 402 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- March 2025
- 175 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 150 Pages
Global
From €4611EUR$4,850USD£3,873GBP
- Report
- February 2024
- 202 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- October 2022
- 194 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- November 2020
- 217 Pages
Global
From €3803EUR$4,000USD£3,195GBP
- Report
- April 2020
- 108 Pages
Global
From €1141EUR$1,200USD£958GBP
- Report
- July 2023
- 210 Pages
Global
From €1892EUR$1,990USD£1,589GBP
- Report
- August 2023
- 370 Pages
Global
From €2367EUR$2,490USD£1,989GBP
- Report
- January 2022
- 105 Pages
Global
From €4516EUR$4,750USD£3,794GBP
- Report
- July 2020
- 213 Pages
China, Global
From €3042EUR$3,200USD£2,556GBP
- Report
- June 2023
- 96 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Book
- October 2012
- 1570 Pages
The Varicella Live Vaccine is a vaccine used to prevent varicella, also known as chickenpox. It is a live attenuated vaccine, meaning it contains a weakened form of the virus. The vaccine is typically given to children between the ages of 12 and 15 months, with a booster dose recommended between the ages of 4 and 6 years. It is also recommended for adults who have not had chickenpox or the vaccine. The vaccine is generally well-tolerated, with mild side effects such as redness, swelling, and soreness at the injection site.
The Varicella Live Vaccine market is a subset of the larger Vaccines market. It is a growing market, with increasing demand for the vaccine due to its effectiveness in preventing varicella. The market is highly competitive, with several companies offering the vaccine.
Some companies in the Varicella Live Vaccine market include Merck & Co., GlaxoSmithKline, Sanofi Pasteur, Pfizer, and AstraZeneca. Show Less Read more
